Safety and tolerability of AdAPT-001 in Phase II trial: no dose-limiting toxicity observed

Anthony Paul Conley, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shared insights on the safety and tolerability of AdAPT-001 in a multicenter Phase II trial (NCT04673942). Surprisingly, no dose-limiting toxicity or serious adverse events directly related to AdAPT-001 were observed. The most common side effects were mild, with grade one flu-like symptoms resolving within 24 to 48 hours post-injection. Additionally, a quarter of patients experienced infusion site reactions, characterized by redness, slight swelling, and mild pain at the injection site, all graded as grade one. These reactions were noted by patients but did not impact their daily activities. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.